Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the recipient of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 2,080,000 shares, a decline of 16.8% from the February 13th total of 2,500,000 shares. Approximately 17.5% of the company’s shares are short sold. Based on an average daily volume of 522,500 shares, the short-interest ratio is currently 4.0 days.

Jasper Therapeutics Stock Down 0.6 %

NASDAQ:JSPR traded down $0.03 during trading hours on Wednesday, reaching $5.19. The company had a trading volume of 222,188 shares, compared to its average volume of 267,512. The firm has a market cap of $77.96 million, a price-to-earnings ratio of -1.09 and a beta of 2.23. The business’s 50-day simple moving average is $5.86 and its two-hundred day simple moving average is $15.49. Jasper Therapeutics has a twelve month low of $4.55 and a twelve month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.35). As a group, equities analysts predict that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on JSPR. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price for the company. Royal Bank of Canada reduced their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday, January 9th. JMP Securities reissued a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research report on Monday, January 6th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Finally, UBS Group began coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $38.00 target price on the stock. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $62.50.

Institutional Trading of Jasper Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of JSPR. BNP Paribas Financial Markets increased its holdings in Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after acquiring an additional 1,698 shares during the period. MetLife Investment Management LLC raised its holdings in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after buying an additional 3,873 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after buying an additional 3,828 shares during the last quarter. EntryPoint Capital LLC bought a new stake in Jasper Therapeutics during the 4th quarter valued at $223,000. Finally, Tema Etfs LLC bought a new position in Jasper Therapeutics in the 4th quarter worth $266,000. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.